Suppr超能文献

健康志愿者渗透压改变时copeptin 与 AVP 的释放和衰减动力学。

Release and Decay Kinetics of Copeptin vs AVP in Response to Osmotic Alterations in Healthy Volunteers.

机构信息

Leipzig University Medical Center, Integrated Center for Research and Treatment Adiposity Diseases, Leipzig, Germany.

Internal Medicine (Endocrinology and Nephrology), University of Leipzig, Germany, Leipzig, Germany.

出版信息

J Clin Endocrinol Metab. 2018 Feb 1;103(2):505-513. doi: 10.1210/jc.2017-01891.

Abstract

CONTEXT

Copeptin is the C-terminal fragment of the arginine vasopressin (AVP) prohormone whose measurement is more robust than that of AVP. Similar release and clearance characteristics have been suggested promoting copeptin as a surrogate marker.

OBJECTIVE

To characterize the physiology of osmotically regulated copeptin release and its half-life in direct comparison with plasma AVP.

DESIGN

Ninety-one healthy volunteers underwent a standardized three-phase test protocol including (1) osmotic stimulation into the hypertonic range by hypertonic-saline infusion followed by osmotic suppression via (2) oral water load and (3) subsequent glucose infusion. Plasma copeptin, AVP, serum sodium, and osmolality levels were measured in regular intervals.

RESULTS

In phase 1, an increase in median osmotic pressure [289 (286; 291) to 311 (309; 314) mOsm/kg H2O] caused similar release kinetics of plasma copeptin [4 (3.1; 6) to 29.3 (18.6; 48.2) pmol/L] and AVP [1 (0.7; 1.6) to 10.3 (6.8; 18.8) pg/mL]. Subsequent osmotic suppression to 298 (295; 301) mOsm/kg at the end of phase 3 revealed markedly different decay kinetics between both peptides-an estimated initial half-life of copeptin being approximately 2 times longer than that of AVP (26 vs 12 minutes).

CONCLUSION

Copeptin is released in equimolar amounts with AVP in response to osmotic stimulation, suggesting its high potential as an AVP surrogate for differentiation of osmotic disorders. Furthermore, we here describe the decay kinetics of copeptin in response to osmotic depression enabling to identify a half-life for copeptin in direct comparison with AVP.

摘要

背景

copeptin 是精氨酸加压素(AVP)前体的 C 端片段,其测量比 AVP 更稳定。类似的释放和清除特征表明 copeptin 可以作为替代标志物。

目的

描述渗透压调节 copeptin 释放的生理学及其与血浆 AVP 的半衰期的直接比较。

设计

91 名健康志愿者接受了标准化的三相测试方案,包括(1)通过高渗盐水输注进入高渗范围的渗透压刺激,随后通过(2)口服水负荷和(3)随后的葡萄糖输注进行渗透压抑制。定期测量血浆 copeptin、AVP、血清钠和渗透压水平。

结果

在第 1 阶段,中位渗透压[289(286;291)至 311(309;314)毫渗/kg H2O]增加引起血浆 copeptin[4(3.1;6)至 29.3(18.6;48.2)pmol/L]和 AVP[1(0.7;1.6)至 10.3(6.8;18.8)pg/mL]的相似释放动力学。在第 3 阶段结束时,渗透压抑制至 298(295;301)毫渗/kg ,两种肽之间的衰减动力学明显不同-估计 copeptin 的初始半衰期大约是 AVP 的 2 倍(26 与 12 分钟)。

结论

copeptin 与 AVP 以等摩尔量释放,以响应渗透压刺激,表明其作为区分渗透压紊乱的 AVP 替代物的高潜力。此外,我们在这里描述了 copeptin 对渗透压抑制的衰减动力学,使我们能够与 AVP 直接比较确定 copeptin 的半衰期。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验